Format

Send to

Choose Destination
Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.

Hepcidin agonists as therapeutic tools.

Author information

1
Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; and.
2
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

Abstract

Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.

PMID:
29523504
PMCID:
PMC5909761
[Available on 2019-04-19]
DOI:
10.1182/blood-2017-11-737411

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center